Our lab studies how epigenetic and metabolic dysregulation influence the development and biology of pediatric brain tumors. My work focuses on a novel epigenetic modifier, EZHIP, which is overexpressed in a subtype of childhood brain cancer known as PF-A ependymomas. EZHIP inhibits polycomb-mediated trimethylation at histone H3 lysine 27 (H3K27me3), a transcriptionally repressive chromatin modifying mark. EZHIP overexpression gives rise to a global reduction in H3K27me3 marks throughout the genome that is poorly prognostic. My project aims to understand the mechanisms regulating EZHIP...